How to buy Summit Therapeutics stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Summit Therapeutics stock

Own Summit Therapeutics stock in just a few minutes.

Fact checked

Summit Therapeutics Inc is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Summit Therapeutics employs 70 staff and has a trailing 12-month revenue of around USD$22.1 million.

How to buy shares in Summit Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Summit Therapeutics. Find the stock by name or ticker symbol: SMMT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Summit Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Summit Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Summit Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Summit Therapeutics share price

Use our graph to track the performance of SMMT stocks over time.

Summit Therapeutics shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$1.42 - USD$10.99
50-day moving average USD$7.0071
200-day moving average USD$4.7858
Wall St. target priceUSD$4.5
PE ratio 1.9918
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.225

Buy Summit Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Summit Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Summit Therapeutics under- or over-valued?

Valuing Summit Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Summit Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Summit Therapeutics's P/E ratio

Summit Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Summit Therapeutics shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Summit Therapeutics financials

Revenue TTM USD$22.1 million
Gross profit TTM USD$17.2 million
Return on assets TTM -36.13%
Return on equity TTM 0%
Profit margin -227.63%
Book value $0.548
Market capitalisation USD$500.4 million

TTM: trailing 12 months

Shorting Summit Therapeutics shares

There are currently 289,991 Summit Therapeutics shares held short by investors – that's known as Summit Therapeutics's "short interest". This figure is 26.1% down from 392,538 last month.

There are a few different ways that this level of interest in shorting Summit Therapeutics shares can be evaluated.

Summit Therapeutics's "short interest ratio" (SIR)

Summit Therapeutics's "short interest ratio" (SIR) is the quantity of Summit Therapeutics shares currently shorted divided by the average quantity of Summit Therapeutics shares traded daily (recently around 295909.18367347). Summit Therapeutics's SIR currently stands at 0.98. In other words for every 100,000 Summit Therapeutics shares traded daily on the market, roughly 980 shares are currently held short.

However Summit Therapeutics's short interest can also be evaluated against the total number of Summit Therapeutics shares, or, against the total number of tradable Summit Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Summit Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Summit Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0072% of the tradable shares (for every 100,000 tradable Summit Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Summit Therapeutics.

Find out more about how you can short Summit Therapeutics stock.

Summit Therapeutics share dividends

We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.

Summit Therapeutics share price volatility

Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $1.42 up to $10.99. A popular way to gauge a stock's volatility is its "beta".

SMMT.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is 0.6259. This would suggest that Summit Therapeutics's shares are less volatile than average (for this exchange).

Summit Therapeutics overview

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site